Login
Companies $GUTS
$1.04 +$0.05 (4.85%) After hours
FRACTYL HEALTH, INC. logo

FRACTYL HEALTH, INC.

fractyl.com

What Do They Do?

Develops Revita, a gut-targeting procedure, and Rejuva, a pancreatic gene therapy platform, for people with obesity or type two diabetes and the physicians and health systems treating them.

Who Are Their Customers?

Revita has had a limited pilot commercial launch in Germany. For a potential U.S. launch, Fractyl plans to work through gastrointestinal endoscopists at centers of excellence and a potential physician-driven platform partner; it also identifies patients, referring physicians, providers and payors as stakeholders.

How Are They Changing?

Since the FY2025 annual report
  • Oct 21, 2026 Fractyl stopped internal Rejuva development and sharpened its focus on Revita The company is seeking strategic alternatives for Rejuva and plans a workforce reduction.
  • Sep 10, 2026 Nasdaq notified Fractyl that its stock faces delisting Fractyl plans to request a hearing, which would stay suspension or delisting while the hearing process continues.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support